Medacta Announces First U.S. Surgery with MectaScrew PEEK following FDA Clearance

EQS Group-Media / 2019-11-04 / 19:00 
 
*Media Release* 
*Medacta Announces First U.S. Surgery with MectaScrew PEEK following FDA 
Clearance* 
 
_CASTEL SAN PIETRO_, _4 November 2019_ - Medacta is proud to announce the 
successful completion of the first U.S. surgery utilizing its MectaScrew 
PEEK Interference Screw for ligament refixation. 
 
The MectaScrew PEEK, which received clearance from the U.S. Food and Drug 
Administration (FDA) in June, is one of Medacta's most recent sports 
medicine offerings. As part of the Medacta Single Bundle ACL set, it is 
intended for knee arthroscopy and indicated for reconstructive treatment of 
ruptured anterior and posterior cruciate ligaments for hamstring and 
bone-tendon-bone repairs. 
 
The MectaScrew PEEK features several noteworthy design features, including a 
blunt thread, which protects the graft from laceration, while ensuring 
fixation strength, as well as sharp threads at the driver tip that gradually 
increase in width as the screw goes from distal to proximal to facilitate 
screw insertion. The associated driver also features a tip design that 
enables strong retention of the screw once positioned on the tip of the 
instrument. 
 
The first single bundle ACL surgery in the United States was completed by 
Akbar Nawab, M.D., at Ellis and Badenhausen Orthopaedics (Louisville, 
Kentucky) on September 24. "The implant and associated instrumentation 
performed very well," said Dr. Nawab. "The screw started nicely and provided 
secure fixation without any damage to the graft, while the instrumentation's 
ergonomic design made each instrument easy and natural to use. I feel very 
confident starting my patient in an accelerated rehabilitation program." 
 
This surgery follows the first single bundle ACL performed in Australia in 
August 2019 and is the start of Medacta's sports medicine presence in the 
United States. 
 
*Contact* 
Medacta International SA 
Gianluca Olgiati 
Senior Director Global Marketing 
Phone: [phone] 
[e-mail] 
 
*About Medacta* 
Medacta is an international company specializing in the design and 
production of innovative orthopaedic products and the development of 
accompanying surgical techniques for joint replacement, spine surgery, and 
sports medicine. Established in 1999 in Switzerland, Medacta's products and 
surgical techniques are characterized by innovation. Medacta is a pioneer in 
developing new offerings on the basis of minimally invasive surgical 
techniques, in particular its Anterior Minimally Invasive Surgery ("AMIS") 
technique for hip replacements. Medacta has leveraged its orthopaedic 
expertise and comprehensive understanding of the human body to develop the 
sophisticated "MySolutions" technology, which offers surgeons highly 
personalized pre-operative planning and implant placement methodologies by 
creating advanced personalized kinematic models and 3D planning tools for 
use in hip, knee, shoulder and spine procedures. 
 
Issuer: Medacta Group SA 
Key word(s): Advertisement/Communication 
 
End of Corporate News 
Language:    English 
Company:     Medacta Group SA 
             Strada Regina 
             6874 Castel San Pietro 
             Switzerland 
Phone:       [phone] 
E-mail:      [e-mail], [e-mail] 
Internet:    www.medacta.com 
ISIN:        CH0468525222 
Listed:      SIX Swiss Exchange 
EQS News ID: 903815 
 
End of News EQS Group Media 
 
903815 2019-11-04 
 
 

(END) Dow Jones Newswires

November 04, 2019 13:00 ET (18:00 GMT)